Legend Biotech Corp Stock: CAR-T Leader in Multiple Myeloma Faces Key Clinical and Market Hurdles

Legend Biotech Corp stands at the forefront of cell therapy innovation, particularly in the treatment of multiple myeloma, a challenging blood cancer. Its lead product, Carvykti, has gained traction as a BCMA-directed CAR-T therapy, approved for relapsed or refractory cases. For North American investors, the company's NASDAQ-listed shares (LEGN) represent a high-stakes play in biotechnology's evolving landscape.

As of: 29.03.2026

By Dr. Elena Vasquez, Senior Biotech Analyst at NorthStar Market Review: Legend Biotech Corp advances CAR-T therapies targeting unmet needs in oncology, positioning it as a key contender in the competitive biotech arena.

Company Overview and Core Business Model

Legend Biotech Corporation, a global clinical-stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel cell therapies for oncology and other indications. Headquartered in Somerset, New Jersey, with significant operations in China through its partnership with Janssen Biotech, the company leverages advanced technologies like CAR-T cell therapy. This approach engineers a patient's T-cells to target cancer cells expressing specific antigens, such as B-cell maturation antigen (BCMA) in multiple myeloma.

The business model centers on collaboration and co-development. Legend's flagship partnership with Janssen, a Johnson & Johnson subsidiary, has been pivotal for Carvykti (ciltacabtagene autoleucel). This therapy received U.S. FDA accelerated approval in 2022 for adults with relapsed or refractory multiple myeloma after four or more prior lines of therapy. Expanded approvals followed, broadening its addressable patient population. Revenue streams primarily stem from product sales and milestone payments under such partnerships.

Manufacturing capacity expansion remains a cornerstone. Legend invests heavily in facilities across the U.S., Europe, and Asia to meet growing demand. This vertical integration aims to reduce costs and improve turnaround times, critical in CAR-T where fresh cell production is required. For investors, this model offers scalability potential as therapies penetrate larger markets.

Lead Product Carvykti and Pipeline Progress

Carvykti represents Legend's commercial cornerstone. As a BCMA-targeted CAR-T, it has demonstrated superior progression-free survival in clinical trials compared to standard treatments. Real-world data supports its efficacy, with durable responses in heavily pretreated patients. The therapy's safety profile, while managing cytokine release syndrome and neurotoxicity common to CAR-Ts, has improved with experience.

Beyond multiple myeloma, Legend advances Carvykti in earlier lines, including frontline settings and combination regimens. Phase 3 trials like CARTITUDE-5 explore its role post-induction therapy, potentially disrupting the treatment paradigm. Positive interim data could unlock significant market share. The company's pipeline extends to other assets, such as LB1908, a solid tumor candidate targeting CLL-1, and preclinical programs in autoimmune diseases.

Regulatory milestones drive value. Recent FDA approvals for expanded indications in Europe and Japan mirror U.S. progress, enhancing global revenue potential. Investors should monitor upcoming data readouts, as they could catalyze stock movements in the volatile biotech sector.

Recent Financial Performance and Market Position

Legend Biotech has shown revenue growth driven by Carvykti commercialization. Quarterly figures indicate strong year-over-year increases, reflecting successful market launches. Earnings have occasionally exceeded analyst expectations, bolstering confidence despite ongoing losses typical in biotech ramp-up phases. Negative margins persist due to high R&D and manufacturing investments.

The stock trades on NASDAQ under LEGN, with a market capitalization placing it among mid-cap biotechs. Institutional ownership remains substantial, signaling long-term interest from funds focused on innovative therapies. Trading volumes support liquidity for North American investors. Shares have experienced volatility, influenced by broader market sentiment toward biotech and cell therapy.

Analyst coverage leans positive, with multiple buy ratings and price targets suggesting upside potential. Coverage from firms like Jefferies underscores belief in the company's trajectory. However, consensus incorporates holds and sells, reflecting diverse views on execution risks.

Strategic Partnerships and Global Reach

The Janssen partnership extends beyond Carvykti development to manufacturing and commercialization. This alliance provides Legend with expertise, funding, and distribution networks, particularly in major markets like the U.S. and Europe. Profit-sharing arrangements incentivize both parties toward rapid adoption.

Legend pursues additional collaborations to diversify. Engagements with academic institutions and other pharma players fuel pipeline advancement. Expansion into China, via its Nanjing facility, taps into a massive patient pool while navigating local regulations. This dual-market strategy mitigates geographic risks.

For North American investors, these ties enhance credibility. Proximity to FDA oversight and U.S. manufacturing sites aligns with domestic priorities. Global diversification, however, introduces currency and regulatory variances to monitor.

Relevance for North American Investors

North American investors find Legend Biotech appealing due to its U.S.-centric approvals and manufacturing. Carvykti's inclusion in NCCN guidelines elevates its status among oncologists. Reimbursement progress with payers like Medicare supports sustained revenue. The company's New Jersey base facilitates engagement with U.S. regulators and investors.

Biotech sector tailwinds, including interest rate environments favoring growth stocks, amplify relevance. Legend's low beta offers relative stability within high-volatility biotech. Portfolio diversification into cell therapy provides exposure to transformative oncology shifts.

What matters now is pipeline catalysts like trial data and label expansions. Investors benefit from monitoring FDA updates and earnings for commercialization metrics. Long-term, achieving profitability could drive re-rating.

Risks and Open Questions for Investors

Biotech investments carry inherent risks, amplified by Legend's pre-profitability status. Clinical trial outcomes remain uncertain; failures or delays in expansions could pressure shares. Competition intensifies from rivals like Bristol Myers Squibb's Abecma and emerging therapies.

Manufacturing scalability poses challenges. Supply chain disruptions or quality issues have historically affected CAR-T availability. High cash burn necessitates funding, though partnerships provide buffers. Geopolitical tensions impacting China operations add uncertainty.

Open questions include path to positive margins and broader pipeline validation. North American investors should watch reimbursement dynamics, competitor readouts, and macroeconomic factors. Diversified exposure mitigates single-stock risks.

Regulatory hurdles persist in new indications. Patient access, measured by vein-to-vein times, influences adoption. Economic pressures on healthcare spending could slow uptake.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.